Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)

Authors

Hun Ju Lee, University of Texas MD Anderson Cancer Center
Michael Y. Choi, University of California San Diego
Tanya Siddiqi, City of Hope
Jacqueline Claudia Barrientos, Northwell Health
William G. Wierda, University of Texas M.D. Anderson Cancer Center
Iris Isufi, Yale University
Joseph M. Tuscano, University of California, Davis
Nicole Lamanna, Columbia University Medical Center
Suki Subbiah, LSUHSC New OrleansFollow
Jean Louise Koff, Emory University
Lori Ann Leslie, John Theurer Cancer Center
Alec Goldenberg, Manhattan Hem Onc Associates
Gina G. Chung, Christ Hospital
James Bradley Breitmeyer, Oncternal Therapeutics

Document Type

Article

Publication Date

5-28-2021

Publication Title

Journal of Clinical Oncology

Volume

39(15_suppl)

Comments

Abstract Number: 7556 2021 ASCO Annual Meeting I

Recommended Citation

Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Barrientos, Jacqueline Claudia; Wierda, William G.; Isufi, Iris; Tuscano, Joseph M.; Lamanna, Nicole; Subbiah, Suki; Koff, Jean Louise; Leslie, Lori Ann; Goldenberg, Alec; Chung, Gina G.; and Breitmeyer, James Bradley, "Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)" (2021). School of Medicine Faculty Publications. 1129.
https://digitalscholar.lsuhsc.edu/som_facpubs/1129